Form 8-K - Current report:
SEC Accession No. 0001193125-25-118805
Filing Date
2025-05-13
Accepted
2025-05-13 16:05:20
Documents
17
Period of Report
2025-05-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d53772d8k.htm   iXBRL 8-K 28318
2 EX-1.1 d53772dex11.htm EX-1.1 177694
3 EX-5.1 d53772dex51.htm EX-5.1 12203
7 GRAPHIC g53772snap1.jpg GRAPHIC 3112
8 GRAPHIC g53772snap2.jpg GRAPHIC 2359
  Complete submission text file 0001193125-25-118805.txt   400678

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20250512.xsd EX-101.SCH 2836
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20250512_lab.xml EX-101.LAB 17995
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20250512_pre.xml EX-101.PRE 11252
19 EXTRACTED XBRL INSTANCE DOCUMENT d53772d8k_htm.xml XML 3655
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 25939945
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)